[go: up one dir, main page]

AR012488A1 - Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion - Google Patents

Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion

Info

Publication number
AR012488A1
AR012488A1 ARP980101843A ARP980101843A AR012488A1 AR 012488 A1 AR012488 A1 AR 012488A1 AR P980101843 A ARP980101843 A AR P980101843A AR P980101843 A ARP980101843 A AR P980101843A AR 012488 A1 AR012488 A1 AR 012488A1
Authority
AR
Argentina
Prior art keywords
alkyl
6alkyl
alkyloxy
mono
procedure
Prior art date
Application number
ARP980101843A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Neurocrine Biosciences Inc filed Critical Janssen Pharmaceutica Nv
Publication of AR012488A1 publication Critical patent/AR012488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a los compuestos derivados de quino- y quinazolinas de formula (I), incluyendo los estereoisomeros y las formas de sal de adicionde ácido farmacéuticamente aceptables de los mismos, donde X es N o CH; R1 es aqluilo C1-6,NR6R7, OR6, SR7; en el caso en el que X es N, R2 representahidrogeno, alquilo C1-6, alquiloxi C1-6 o alquiltio C1-6; en el caso en el que X es CH, R2 representa alquilo C1-6, alquiloxi C1-6 o alquiltio C1-6; R3 es Ar1o Het1; R4 y R5 están cada unoindepe ndientemente seleccionados de hidrogeno, halo, alquilo C1-6, alquiloxi C1-6, trifluormetilo, ciano, nitro, amino, ymono- o di(alquilo C1-6)amino, R6 es hidrogeno, alquilo C1-8, mono- o di (cicloalquilo C3-6)metilo, cicloalquilooC3-6, alquen ilo C3-6, hidroxi alquiloC1-6, alquilcarboniloxi C1-6, alquilo C1-6 o alquiloxi C1-6 alquilo C1-6; R7 es alquilo C1-8, mono- o di-(cicloalquilo C3-6)metilo, Ar2CH2, alquiloxi C1-6alquilo C1-6, hidroxialquilo C1-6, alquenilo C3-6,tienilmetilo, furani lmetilo, alquiltio C1-6, alquilo C1-6, mono- o di-(alquilo C1-6)amino alquilo C1-6; o R6y R7 tomados conjuntamente con el átomos de nitrogeno al cual están unidos pueden formar un grupo pirrolidinilo, piperidinilo,homopiperidinilo omorfolinilo, opcionalmente sustituido con alquilo C1-6 o alquiloxi C1-6 alquilo C1-6; y Ar1 y Ar2 son cada uno fenilo opcionalmente substituido; y Het1es piridinilo opcionalmente substituido; que tiene propiedadesantagonistas del receptor de CRF; co mposiciones farmacéuticas que contienen dichoscompuestos como ingredientes activos, métodos de tratamiento de desordenes relacionados con hipersecrecion de CRF tales como depresion, ansiendad, abusodesubstancias adictivas, mediante la administr acion de una cantidad eficaz de una compuesto de formula (I).
ARP980101843A 1997-04-22 1998-04-21 Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion AR012488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4452597P 1997-04-22 1997-04-22

Publications (1)

Publication Number Publication Date
AR012488A1 true AR012488A1 (es) 2000-10-18

Family

ID=21932877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101843A AR012488A1 (es) 1997-04-22 1998-04-21 Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion

Country Status (16)

Country Link
US (3) US6482836B1 (es)
EP (1) EP0977737B1 (es)
JP (1) JP2002501492A (es)
KR (1) KR20000069311A (es)
AR (1) AR012488A1 (es)
AT (1) ATE250035T1 (es)
AU (1) AU7644698A (es)
CA (1) CA2272291C (es)
DE (1) DE69818248T2 (es)
DK (1) DK0977737T3 (es)
ES (1) ES2207834T3 (es)
NZ (1) NZ335822A (es)
PT (1) PT977737E (es)
TW (1) TW593280B (es)
WO (1) WO1998047874A1 (es)
ZA (1) ZA983358B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
AU7644698A (en) * 1997-04-22 1998-11-13 Janssen Pharmaceutica N.V. Crf antagonistic quino- and quinazolines
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CZ20021086A3 (cs) 1999-09-30 2002-10-16 Neurogen Corporation Alkylendiaminem substituované heterocykly
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU2003219103B2 (en) 2002-03-27 2008-10-23 Axovant Sciences Gmbh Quinoline derivatives and their use as 5-HT6 ligands
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
ATE374190T1 (de) * 2003-08-12 2007-10-15 Hoffmann La Roche Tetrahydrochinazolinderivate als cfr-antagonisten
PT2210607E (pt) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolina-4-ilpropil)oxi]quinolina-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida para o tratamento do cancro
JP2008521901A (ja) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド ５−フェニル−５，６，７，８−ヒドロキノリンタキキニン受容体拮抗薬
WO2006060346A2 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
US8420670B2 (en) * 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
SI3096756T1 (sl) 2014-01-21 2024-09-30 Neurocrine Biosciences, Inc. CRF1 receptorski antagonisti za zdravljenje kongenitalne adrenalne hiperplazije
JP6895378B2 (ja) 2015-01-06 2021-06-30 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
BR112021010847A2 (pt) 2018-12-07 2021-09-08 Neurocrine Biosciences Inc. Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110347A (en) * 1990-11-26 1992-05-05 E. I Du Pont De Nemours And Company Substituted fused heterocyclic herbicides
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
CA2194756A1 (en) * 1995-05-12 1996-11-14 Jun Yuan Novel deazapurine derivatives; a new class of crf1 specific ligands
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO1998029397A1 (fr) * 1996-12-27 1998-07-09 Yoshitomi Pharmaceutical Industries, Ltd. Composes pyrimidine a anneaux condenses et leur utilisation medicinale
AU7644698A (en) * 1997-04-22 1998-11-13 Janssen Pharmaceutica N.V. Crf antagonistic quino- and quinazolines
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.

Also Published As

Publication number Publication date
CA2272291A1 (en) 1998-10-29
EP0977737A1 (en) 2000-02-09
NZ335822A (en) 2001-05-25
TW593280B (en) 2004-06-21
KR20000069311A (ko) 2000-11-25
ATE250035T1 (de) 2003-10-15
ES2207834T3 (es) 2004-06-01
EP0977737B1 (en) 2003-09-17
WO1998047874A1 (en) 1998-10-29
DK0977737T3 (da) 2004-01-26
ZA983358B (en) 1999-10-21
CA2272291C (en) 2008-06-17
DE69818248D1 (de) 2003-10-23
AU7644698A (en) 1998-11-13
US20040121998A1 (en) 2004-06-24
US6482836B1 (en) 2002-11-19
PT977737E (pt) 2004-02-27
US6610678B2 (en) 2003-08-26
US20030119818A1 (en) 2003-06-26
DE69818248T2 (de) 2004-06-17
JP2002501492A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
AR012488A1 (es) Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR008577A1 (es) Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion
ES2167710T3 (es) Tiofenopirimidinas.
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
MX9206634A (es) Composiciones farmaceuticas para uso oral y metodo para su preparacion.
AR037235A1 (es) Derivados de sulfonamida, medicamentos que los contienen y el uso de dichos derivados para la preparacion de medicamentos
ES2060910T3 (es) Peptidos que tienen actividad antagonista de taquiquinina, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
AR047008A1 (es) Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos.
YU84791A (sh) Biciklicni 1-aza-cikloalkalni
RU2343145C2 (ru) Производные изоиндолина
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
ES2061462T3 (es) Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2179353T3 (es) Antagonistas muscarinicos.
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
DK1463487T3 (da) Liposomal afgivelse af vitamin-E baserede forbindelser
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal